Kura Oncology, Inc. (KURA) Given Average Recommendation of “Buy” by Brokerages

Kura Oncology, Inc. (NASDAQ:KURA) has received an average recommendation of “Buy” from the nine research firms that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $18.30.

Several research analysts have weighed in on the company. Oppenheimer set a $18.00 price target on Kura Oncology and gave the company a “buy” rating in a report on Thursday, November 16th. BidaskClub upgraded Kura Oncology from a “hold” rating to a “buy” rating in a report on Wednesday, January 24th. Cann reiterated a “buy” rating on shares of Kura Oncology in a report on Wednesday, November 8th. Zacks Investment Research upgraded Kura Oncology from a “hold” rating to a “buy” rating and set a $17.00 price target for the company in a report on Monday, October 2nd. Finally, Wedbush assumed coverage on Kura Oncology in a report on Tuesday, December 26th. They issued a “buy” rating and a $19.00 price target for the company.

Shares of Kura Oncology (NASDAQ:KURA) opened at $19.95 on Monday. Kura Oncology has a 52 week low of $5.78 and a 52 week high of $20.80. The company has a quick ratio of 13.48, a current ratio of 13.48 and a debt-to-equity ratio of 0.07. The stock has a market capitalization of $602.80 and a P/E ratio of -12.87.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Tuesday, November 7th. The company reported ($0.38) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.01). equities analysts forecast that Kura Oncology will post -1.52 earnings per share for the current year.

Institutional investors and hedge funds have recently modified their holdings of the business. Rhumbline Advisers acquired a new position in Kura Oncology in the 2nd quarter valued at $131,000. New York State Common Retirement Fund acquired a new stake in shares of Kura Oncology during the 2nd quarter worth $142,000. OxFORD Asset Management LLP acquired a new stake in shares of Kura Oncology during the 2nd quarter worth $217,000. Schwab Charles Investment Management Inc. acquired a new stake in shares of Kura Oncology during the 2nd quarter worth $226,000. Finally, California State Teachers Retirement System acquired a new stake in shares of Kura Oncology during the 2nd quarter worth $235,000. Institutional investors own 62.96% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Kura Oncology, Inc. (KURA) Given Average Recommendation of “Buy” by Brokerages” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/29/kura-oncology-inc-kura-given-average-recommendation-of-buy-by-brokerages.html.

Kura Oncology Company Profile

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply